



INSTITUTE OF BIOPHYSICS
HEBEI UNIVERSITY OF TECHNOLOGY

IBP.HUT



Natural compounds targeting at ion channels are potential antitumor drugs



An Hailong

Hebei University of Technology

November 27, 2018

CONTENTS



河北工业大学
HEBEI UNIVERSITY OF TECHNOLOGY

01

Introduction


02

**Drug screening
targeting at CaCCs**


03

**Drug screening
targeting at Kv10.1**

Ion channels and Membrane.



No ions can permeate membrane directly.




There are numerous ion channels implanting in the membrane.


Ion channel: the basis of electro-activities.



Heart rates



Brain signals



Neuro-signals


Ion channel: the basis of feelings.



sour



bitter



pain




hot




cold

Ion channels transit its conformation response to diverse stimuli.



Science, (2016), **353** 664-669.

Ion channel related diseases and targeted drugs design.



Binding with the ligands regulates the function of ion channels.

Ion channels represent the second largest target for existing drugs after G protein-coupled receptors.

NO.	Ion channel	Cancer
1	Kv1.1	Macrophages ¹
2	Kv1.3	Blood cells ² , Melanoma ³
3	Kv1.5	Macrophages ¹
4	Kv10.1	Breast⁴⁻⁶,cervix⁷,neuroblastoma⁸,colon⁹, ovary¹⁰, head and neck, Sarcoma¹¹, AML¹²
5	Kv10.2	Medulloblastoma ¹³
6	Kv11.1	Thyroid ¹⁴ , breast ¹⁵ , Glioblastoma ¹⁶ , gastric ¹⁷ , colon ¹⁸ , ovary ¹⁹ , head and neck ²⁰
7	Kir1.1	Blood cells ^{21,22}
8	Kir3.4	Adrenal ²³
9	K2p5.1	Breast ²⁴
10	K2p9.1	Breast ^{25,26} , neurons ²⁷ , lung ²⁷ , glioma ²⁸ , Ovary ²⁹
11	KCa1.1	Neurons ³⁰ , glioma ³¹⁻³³ ,
12	KCa2.3	Breast ³⁴
13	KCa3.1	Glioma ^{33,35,36} , Vascular smooth muscle ³⁷ , colon ³⁸ , breast ³⁴
14	Nav1.2	Mesothelioma ³⁹ , Cervix ⁴⁰
15	Nav1.5	Breast ⁴¹ , non-small cell lung cancer ⁴² , Lymphoma ⁴³
16	Nav1.6	Cervix ⁴⁰
17	Nav1.7	Prostate ⁴⁴ , Cervix ⁴⁰
18	Hv1	Colon ⁴⁵ , glioma ⁴⁶
19	Cav3.1	Glioma ⁴⁷⁻⁴⁹ , Neuroblastoma ⁵⁰ , Breast ⁵¹ , Retinoblastoma ⁵² , Fibrosarcoma ⁵³
20	Cav3.2	Glioma ⁴⁷⁻⁴⁹ , Breast ⁵¹ , Prostate ⁵⁴ , Pheochromocytoma ⁵⁵ , Leukemogenesis ^{56,57}
21	TRPM1	Melanoma ⁵⁸⁻⁶⁰
22	TRPM5	Melanoma ⁵⁸
23	TRPM7	Breast ⁶¹
24	TRPM8	Prostate ⁶²⁻⁶⁴
25	TRPV1	Prostate ⁶⁵ , bladder ⁶⁶ , colon ⁶⁷ , pancreas ⁶⁸
26	TRPV6	Prostate ^{69,70} , breast ⁷¹ , Colon ⁷²
27	CLC3	Glioma ⁷³
28	Ano1	Breast⁷⁴, head and neck⁷⁵,lung⁷⁶, gastric cancer⁷⁷
29	Ano6	Breast ⁷⁸
30	Ano7	Prostate ^{79,80}




Focused issues by our lab.

- **Function and structure relations : Kir channels, CaCCs, Kv channels.**
- **Ion channel and disease : CaCCs and Kv channels with evolution of cancer.**
- **Drug screening and optimization targeting at ion channels.**

JBC (2012), JMB(2011, 2013, 2015, 2017×2 , 2018), JCAMD (2013, 2015), PLoS ONE (2014, 2017), Scientific Reports (2015), MNB(2016), EJP(2017), IJBM(2017), CPL(2015, 2016, 2017), Channels (2016), Proteins (2016), BJP(2011, 2014, 2015), JCP(2018×2).



Currents mediated by calcium-activated chloride channels (CaCCs) were first observed in the early 1980's in *Xenopus* oocytes (1,2) and salamander photoreceptors (3).




CaCCs were first recorded in oocytes.

Proc R Soc Lond B Biol Sci 1982, *J Physiol* 1983, *J Physiol* 1982.




CaCCs (Calcium activated chloride currents) have been detected in variety of tissues in human bodies and play important roles in variety of physiological processes.




TMEM16A & B belonging to TMEM16 family are the molecular basis for CaCCs.



Kv10.1 channel, a voltage dependent gating potassium channel, belongs to the EAG subfamily which has two members.



Unlike CaCCs, Kv10.1 channel is rarely discovered in normal tissues, no distribution in the heart, however, its dysfunction is associated with 12 malignancies - an ideal anti-tumor drug target.



[1] Sensors, 2012, 12(5), 5986-5995.

[2] Cancer Research, 2004, 64(19), 6996-7001.

[3] Embo Journal, 1999, 18(20), 5540-5547.




[4] Pflügers Archiv - European Journal of Physiology, 2016, 468(5), 751-762.

[5] Diagnostic pathology, 2010 5(1), 78.




Anti-tumor drug screening Targeting at CaCCs

2. CaCCs/TMEM16A inhibitor discovery--Matrine




Matrine can inhibit TMEM16A channel

2. CaCCs/TMEM16A inhibitor discovery---Matrine




Matrine concentration-dependent inhibit the TMEM16A currents

2. CaCCs/TMEM16A inhibitor discovery---Matrine




Determination of binding site of Matrine with TMEM16A

2. CaCCs/TMEM16A inhibitor discovery---Matrine






Matrine inhibited the proliferation of LA795 cells by inhibiting TMEM16A

2. CaCCs/TMEM16A inhibitor discovery---Matrine




Matrine inhibited the migration of LA795 cells by inhibiting TMEM16A

2. CaCCs/TMEM16A inhibitor discovery---Matrine



The effect of Matrine disappeared when TMEM16A were knocked out

2. CaCCs/TMEM16A inhibitor discovery---Matrine




Matrine inhibits lung tumor growth by inhibiting TMEM16A to induce cell apoptosis





Anti-tumor drug screening targeting at Kv10.1

3. Anti-tumor drug screening targeting at Kv10.1.






Characterization of Eag1 currents in stably transfected CHO cells.


3. Anti-tumor drug screening targeting at Kv10.1.



E




F




Currents inhibited by various concentrations of tetrandrine in CHO cells stably expressing Eag1

3. Anti-tumor drug screening targeting at Kv10.1.


A



B




C




Inhibition mechanism of Eag1 by tetrandrine that includes no $[Ca^{2+}]_i$ changes.

3. Anti-tumor drug screening targeting at Kv10.1.




Molecular determination of tetrandrine sensitivity.

3. Anti-tumor drug screening targeting at Kv10.1.



Effects of different concentrations of tetrandrine on CHO cells stably expressing Eag1 and HeLa cells.

3. Anti-tumor drug screening targeting at Kv10.1.



The Eag1 inhibitor tetrandrine reduces tumour growth *in vivo*.



致 谢

张海林 教授

河北医科大学

龙勉 研究员

吕守芹 研究员

中科院 力学所

李英贤 研究员

中国航天员科研训练中心

刘文欣 主任医师

天津肿瘤医院

苏继国 教授

燕山大学

Dr. D. E. Logothetis

Virginia Commonwealth
University, USA

- 国家自然科学基金重点项目：11735006, 80830861;
- 国家自然科学基金：11747610, 11475053；
- 河北省杰出青年科学基金：C2015202340。
- 河北省高校百名优秀创新人才支持计划;
- 河北省高层次人才支持计划；
- 河北省生物物理重点学科。



IICC-5

The 5th International Ion Channel Conference

第五届国际离子通道大会

June 26 – June 30, 2015 Luzhou, China

Host Organization/承办单位: Sichuan Medical University

Co-Organization/协办单位:



Thanks for your attention.



河北工业大学文件

校政字〔2016〕317号

签发人：张建畅

关于印发《河北工业大学“元光学者计划” 实施办法（试行）》的通知

关于印发《河北工业大学元光学者计划 实施办法（试行）》的通知							
人才 层次	岗位名称	学科建设经费	住房补贴 及安家费 （万元）	（元/月） 或高层次 人才周转 住房	工资	元光学者 津贴 （万元/年）	备注
一层次	卓越岗	2000 （可面议）	500 （可面议）	4000	基本工资 + 绩效工资	100	年薪≥ 150 万元
二层次	领军岗 A	理工科 800-1000 人文社科或经管类 300-500	300	3000		60	年薪≥ 90 万元
	领军岗 B	理工科 600-800 人文社科或经管类 200-300	250			45	
三层次	特聘岗 A	理工科 300-500 人文社科或经管类 100-200	200	2500		40	年薪≥ 60 万元
	特聘岗 B	理工科 150-400 人文社科或经管类 50-100	150			25	
四层次	启航岗 A	理工科 100-200 人文社科或经管类 30-50	100	2000		15	
	启航岗 B	理工科:30-50 人文社科或经管类:10-30	80			8	